Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Tonix Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 GlobeNewswire Jun 16, 2025, 11:00:00 AM ...

Tonix Pharmaceuticals TNXP reported positive Phase 3 study results for its non-opioid painkiller in late December. The drug lowered the characteristic widespread pain in fibromyalgia reported by ...

Tonix Pharmaceuticals earnings report for the third quarter of 2024 (Q3 2024) revealed a net loss of $14.2 million, or $0.23 per share, which significantly improved on the consensus estimate by $1.80.

Summary. Initiate Hold rating on Tonix Pharmaceuticals due to increased approval odds for TNX-102 SL but concerns over commercial prospects and potential shareholder dilution.

Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...